NASDAQ:EYES Second Sight Medical Products Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Second Sight Medical Products Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.86 +0.03 (+3.61 %) (As of 09/28/2020 01:37 PM ET) Add Compare Share Today's Range$0.83Now: $0.86▼$0.8650-Day Range$0.73MA: $0.84▼$1.0352-Week Range$0.69Now: $0.86▼$7.60Volume2,210 shsAverage Volume508,660 shsMarket Capitalization$19.88 millionP/E RatioN/ADividend YieldN/ABeta2.19 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSecond Sight Medical Products has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.25, Second Sight Medical Products has a forecasted upside of 163.4% from its current price of $0.85.Amount of Analyst CoverageSecond Sight Medical Products has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSecond Sight Medical Products has received 260 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSecond Sight Medical Products has received 279 “underperform” votes. (Add your “underperform” vote.)Community SentimentSecond Sight Medical Products has received 51.76% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote “Outperform” if you believe EYES will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSecond Sight Medical Products does not currently pay a dividend.Dividend GrowthSecond Sight Medical Products does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Second Sight Medical Products insiders have not sold or bought any company stock.Percentage Held by Insiders67.52% of the stock of Second Sight Medical Products is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.63% of the stock of Second Sight Medical Products is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Second Sight Medical Products is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Second Sight Medical Products is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSecond Sight Medical Products has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYES Previous Symbol CUSIPN/A CIK1266806 Webwww.secondsight.com Phone818-833-5000Debt Debt-to-Equity RatioN/A Current Ratio1.68 Quick Ratio1.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.38 million Price / Sales5.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book1.83Profitability EPS (Most Recent Fiscal Year)($1.91) Net Income$-33,590,000.00 Net Margins-994.14% Return on Equity-470.66% Return on Assets-213.55%Miscellaneous Employees123 Outstanding Shares23,118,000Market Cap$19.88 million Next Earnings Date11/12/2020 (Estimated) OptionableOptionable $0.86 +0.03 (+3.61 %) (As of 09/28/2020 01:37 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EYES News and Ratings via Email Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter. Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions How has Second Sight Medical Products' stock been impacted by COVID-19 (Coronavirus)? Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EYES shares have decreased by 75.6% and is now trading at $0.86. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Second Sight Medical Products? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Second Sight Medical Products. When is Second Sight Medical Products' next earnings date? Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Second Sight Medical Products. How were Second Sight Medical Products' earnings last quarter? Second Sight Medical Products Inc (NASDAQ:EYES) issued its earnings results on Thursday, August, 13th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 470.66%. View Second Sight Medical Products' earnings history. What price target have analysts set for EYES? 2 brokers have issued twelve-month price objectives for Second Sight Medical Products' shares. Their forecasts range from $2.00 to $2.50. On average, they anticipate Second Sight Medical Products' stock price to reach $2.25 in the next year. This suggests a possible upside of 161.6% from the stock's current price. View analysts' price targets for Second Sight Medical Products. Are investors shorting Second Sight Medical Products? Second Sight Medical Products saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 424,000 shares, a decrease of 30.7% from the August 31st total of 611,900 shares. Based on an average trading volume of 475,800 shares, the short-interest ratio is currently 0.9 days. Approximately 3.4% of the company's stock are sold short. View Second Sight Medical Products' Short Interest. Who are some of Second Sight Medical Products' key competitors? Some companies that are related to Second Sight Medical Products include electroCore (ECOR), Fc Global Realty (FCRE), IRIDEX (IRIX), Reshape Lifesciences (RSLS), CHF Solutions (CHFS), Helius Medical Technologies (HSDT), Helius Medical Technologies (HSDT), ENDRA Life Sciences (NDRA), Precision Optics (PEYE), Digirad (DRAD), Viveve Medical (VIVE), Micron Solutions (MICR), Guided Therapeutics (GTHP), Vaso (VASO) and Non-Invasive Monitoring Systems (NIMU). View all competitors. What other stocks do shareholders of Second Sight Medical Products own? Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), VBI Vaccines (VBIV), Canopy Growth (CGC), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Ekso Bionics (EKSO) and Opko Health (OPK). Who are Second Sight Medical Products' key executives? Second Sight Medical Products' management team includes the following people: Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)Mr. John T. Blake, CFO & Corp. Sec. (Age 43)Mr. William Patrick Ryan, Chief Operating Officer (Age 58)Gunnar Bjorg, FounderMr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55) When did Second Sight Medical Products IPO? (EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO. What is Second Sight Medical Products' stock symbol? Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES." Who are Second Sight Medical Products' major shareholders? Second Sight Medical Products' stock is owned by a variety of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View institutional ownership trends for Second Sight Medical Products. Which institutional investors are buying Second Sight Medical Products stock? EYES stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View insider buying and selling activity for Second Sight Medical Products. How do I buy shares of Second Sight Medical Products? Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Second Sight Medical Products' stock price today? One share of EYES stock can currently be purchased for approximately $0.86. How big of a company is Second Sight Medical Products? Second Sight Medical Products has a market capitalization of $19.88 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe. What is Second Sight Medical Products' official website? The official website for Second Sight Medical Products is www.secondsight.com. How can I contact Second Sight Medical Products? Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
